论文部分内容阅读
目的 :观察国产重组链激酶 (r -sk)对急性心肌梗死 (AMI)静脉溶栓的治疗和不良反应 ,对其安全性和疗效做出评价。方法 :所有病例均符合入选和不入选标准 ,予r -sk 15 0万单位于 6 0分钟内静滴 ,观察血管再通的临床指标及不良反应。结果 :6 4例患者血管再通率为 82 .8% ,出血发生率为 9.38% ,表现为胃肠道轻微出血 ,未经特殊处理自行消失。结论 :r -sk静脉溶栓再通率高 ,不良反应少 ,为一安全有效的溶栓剂。
Objective: To observe the treatment and adverse reactions of domestic recombinant streptokinase (r -sk) on intravenous thrombolysis in patients with acute myocardial infarction (AMI) and to evaluate its safety and efficacy. Methods: All patients were eligible for inclusion and non-inclusion criteria, to r -sk 150 million units intravenous infusion within 60 minutes to observe the clinical indicators of recanalization and adverse reactions. Results: The vascular recanalization rate was 82.8% in 6 4 patients and the bleeding rate was 9.38%. The gastrointestinal tract showed mild bleeding and disappeared without special treatment. Conclusion: r-ssk intravenous thrombolysis recanalization rate, fewer adverse reactions, as a safe and effective thrombolytic agent.